- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00062257
Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer
A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer
RATIONALE: Drugs used in chemotherapy, such as irofulven, use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well irofulven works in treating patients with recurrent or metastatic gastric cancer.
Studienübersicht
Detaillierte Beschreibung
OBJECTIVES:
- Determine the response rate of patients with recurrent or metastatic gastric cancer treated with irofulven.
- Determine the toxicity profile of this drug in these patients.
- Determine the overall survival of patients treated with this drug.
OUTLINE: This is a non-randomized, open-label, multicenter study.
Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks in the absence of disease progression, unacceptable toxicity, or static disease after 4 courses in the absence of clinical benefit.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 5-9 months.
Studientyp
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2050
- Sydney Cancer Centre at Royal Prince Alfred Hospital
-
-
-
-
-
Shatin, New Territories, Hongkong
- Prince of Wales Hospital
-
-
-
-
-
Seoul, Korea, Republik von, 120-752
- Yonsei Cancer Center at Yonsei University Medical Center
-
-
-
-
-
Singapore, Singapur, 169610
- National Cancer Centre - Singapore
-
Singapore, Singapur, 119074
- Cancer Institute at National University Hospital
-
Singapore, Singapur, 119074
- Johns Hopkins - Singapore
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed gastric adenocarcinoma
- Recurrent or metastatic disease
- Adenocarcinoma of the gastroesophageal junction eligible provided the majority of tumor bulk is below the junction
Measurable disease
- At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- Over 18
Performance status
- ECOG 0-2
Life expectancy
- More than 3 months
Hematopoietic
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- No active disseminated intravascular coagulation
Hepatic
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST/ALT no greater than 2.5 times ULN (5 times ULN for patients with liver metastases)
- Alkaline phosphatase no greater than 5 times ULN
Renal
- Creatinine no greater than 1.5 times ULN
Cardiovascular
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior allergic reaction attributed to compounds of similar chemical or biological composition to irofulven
- No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
- No other uncontrolled concurrent illness that would preclude study participation
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study compliance
- Must have central or peripherally inserted central catheter
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa
Chemotherapy
- No prior chemotherapy for recurrent or metastatic disease
- Prior adjuvant or neoadjuvant chemotherapy allowed provided disease relapsed more than 6 months after therapy
Endocrine therapy
- Not specified
Radiotherapy
- More than 4 weeks since prior radiotherapy and recovered
Surgery
- Not specified
Other
- No other concurrent investigational or commercial agents or therapies for the malignancy
- No concurrent combination antiretroviral therapy for HIV-positive patients
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Maskierung: Keine (Offenes Etikett)
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Winnie Yeo, Prince of Wales Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Neubildungen
- Neubildungen nach Standort
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Magenerkrankungen
- Magenneoplasmen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Irofulven
Andere Studien-ID-Nummern
- CTRG-G15/02
- CDR0000304669 (Registrierungskennung: PDQ (Physician Data Query))
- NCI-6041
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Magenkrebs
-
Assiut UniversityNoch keine RekrutierungGAVE - Gastric Antral Vascular Ectasie
-
H. Lee Moffitt Cancer Center and Research InstituteColumbia University; University Hospitals Cleveland Medical Center; Geisinger... und andere MitarbeiterSuspendiertBlutung | GAVE - Gastric Antral Vascular Ectasie | Blutender MagenVereinigte Staaten